Under the terms of the agreement, Gilead will provide an upfront payment of $10 million. Additionally, Hookipa will be eligible to receive milestone payments based upon the achievement of specified development, regulatory, and commercial milestones up to a total of more than $400 million.
Gilead will fund all research and development activities. Hookipa will also be eligible to receive tiered royalties on net sales.
Hookipa CEO Joern Aldag said: "Gilead, a world leader in innovative therapies against major viral diseases, is the ideal partner for us to drive our pipeline development in this area for the benefit of patients in need. This partnership is strong recognition of our unique immunization technology, and helps us concentrate our own energy and resources on immuno-oncology.
"The collaborative HIV and HBV programs nicely complement our significant efforts in the infectious disease area with an exciting proprietary prophylactic CMV vaccine.”
Gilead research executive vice president Bill Lee said: “Gilead is committed to advancing innovative approaches directed at functional cures against HIV and HBV.
“We are convinced that Hookipa’s unique therapeutic vaccine technology, which has demonstrated excellent safety and immunogenicity in Phase 1 clinical studies, has strong potential to have synergistic effect with other Gilead cure efforts in both of these diseases areas.
“Our ultimate long-term goal is to eliminate the need for life-long antiviral therapy for millions of patients around the world.”
Source: Company Press Release.